{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:41:50Z","timestamp":1769215310060,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.xphs.2020.11.016","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T02:07:11Z","timestamp":1606356431000},"page":"1316-1322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Aerosol Inhalation Delivery of Triazavirin in Mice: Outlooks for Advanced Therapy Against Novel Viral Infections"],"prefix":"10.1016","volume":"110","author":[{"given":"Sergey V.","family":"Valiulin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey A.","family":"Onischuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey N.","family":"Dubtsov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anatoly M.","family":"Baklanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey V.","family":"An'kov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Plokhotnichenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana G.","family":"Tolstikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina G.","family":"Dultseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir L.","family":"Rusinov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valery N.","family":"Charushin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasily M.","family":"Fomin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.xphs.2020.11.016_bib1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","article-title":"Ongoing clinical trials for the management of the COVID-19 pandemic","volume":"41","author":"Lythgoe","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"69","key":"10.1016\/j.xphs.2020.11.016_bib2","first-page":"1","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"issue":"6","key":"10.1016\/j.xphs.2020.11.016_bib3","first-page":"9","article-title":"A\u00a0new antiviral drug Triazavirin: results of phase II clinical trial","volume":"57","author":"Kiselev","year":"2012","journal-title":"Vopr Virusol"},{"key":"10.1016\/j.xphs.2020.11.016_bib4","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1080\/07391102.2017.1367329","article-title":"Triazavirine supramolecular complexes as modifiers of the peptide oligomeric structure","volume":"36","author":"Shvetsov","year":"2018","journal-title":"J\u00a0Biomol Struct Dyn"},{"key":"10.1016\/j.xphs.2020.11.016_bib5","first-page":"20","article-title":"New antiviral drug Triazavirin. Results of phase 1 clinical trial","author":"Deeva","year":"2013","journal-title":"Epidemiol Infect Dis"},{"issue":"11-12","key":"10.1016\/j.xphs.2020.11.016_bib6","first-page":"18","article-title":"The study of antiviral activity of Triazavirin in relation to the influenzavirusA(H5N1) (causative agent of influenza) on cellular culture","volume":"52","author":"Loginova","year":"2007","journal-title":"Antibiot Chemother"},{"issue":"2","key":"10.1016\/j.xphs.2020.11.016_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.17816\/KMJ2018-215","article-title":"Study of effectiveness of antiviral drugs (umifenovir, triazavirin) against acute respiratory viral infections","volume":"99","author":"Tikhonova","year":"2018","journal-title":"Kazan Med J"},{"key":"10.1016\/j.xphs.2020.11.016_bib8","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1128\/AAC.01186-09","article-title":"Antiviral properties, metabolism, and pharmacokinetics of a novel Azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication","volume":"54","author":"Karpenko","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.xphs.2020.11.016_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.06.011","article-title":"The efficacy and safety of triazavirin for COVID-19: a trial protocol","author":"Wu","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.xphs.2020.11.016_bib11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/med.20140","article-title":"Nanoparticle formulations in pulmonary drug delivery","volume":"29","author":"Bailey","year":"2009","journal-title":"Med Res Rev"},{"key":"10.1016\/j.xphs.2020.11.016_bib12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S2213-2600(13)70072-9","article-title":"Pulmonary drug delivery: from generating aerosols to overcoming biological barriers - therapeutic possibilities and technological challenges","volume":"1","author":"Ruge","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.xphs.2020.11.016_bib13","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1183\/09031936.05.00017305","article-title":"Aerosol delivery of chemotherapy in an orthotopic model of lung cancer","volume":"26","author":"Gagnadoux","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.xphs.2020.11.016_bib14","first-page":"1161","article-title":"The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination","volume":"50","author":"Laube","year":"2005","journal-title":"Respir Care"},{"key":"10.1016\/j.xphs.2020.11.016_bib15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/rr58","article-title":"The lung as a route for systemic delivery of therapeutic proteins and peptides","volume":"2","author":"Agu","year":"2001","journal-title":"Respir Res"},{"key":"10.1016\/j.xphs.2020.11.016_bib16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1513\/pats.200409-049TA","article-title":"The lungs as a portal of entry for systemic drug delivery","volume":"1","author":"Patton","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.xphs.2020.11.016_bib17","first-page":"588","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.xphs.2020.11.016_bib18","series-title":"Pharmaceutical Inhalation Aerosol Technology","year":"2004"},{"key":"10.1016\/j.xphs.2020.11.016_bib19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/jamp.2007.0672","article-title":"Anti-inflammatory effect from indomethacin nanoparticles inhaled by male mice","volume":"21","author":"Onischuk","year":"2008","journal-title":"J\u00a0Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.xphs.2020.11.016_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/jamp.2008.0721","article-title":"Analgesic effect from ibuprofen nanoparticles inhaled by male mice","volume":"22","author":"Onischuk","year":"2009","journal-title":"J\u00a0Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.xphs.2020.11.016_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jaerosci.2016.05.005","article-title":"Ibuprofen, indomethacin and diclofenac sodium nanoaerosol: generation, inhalation delivery and biological effects in mice and rats","volume":"100","author":"Onischuk","year":"2016","journal-title":"J\u00a0Aerosol Sci"},{"key":"10.1016\/j.xphs.2020.11.016_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaerosci.2014.08.004","article-title":"Generation, inhalation delivery and anti-hypertensive effect of nisoldipine nanoaerosol","volume":"78","author":"Onischuk","year":"2014","journal-title":"J\u00a0Aerosol Sci"},{"key":"10.1016\/j.xphs.2020.11.016_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2019.03.050","article-title":"Excipient-free isoniazid aerosol administration in mice: evaporation-nucleation particle generation, pulmonary delivery and body distribution","volume":"563","author":"Valiulin","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.11.016_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0169-8095(02)00010-8","article-title":"Intercomparison of number concentration measurements by various aerosol particle counters","volume":"62","author":"Ankilov","year":"2002","journal-title":"Atmos Res"},{"key":"10.1016\/j.xphs.2020.11.016_bib25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaerosci.2016.10.015","article-title":"Laboratory verification of Aerosol Diffusion Spectrometer and the application to ambient measurements of new particle formation","volume":"105","author":"Dubtsov","year":"2017","journal-title":"J\u00a0Aerosol Sci"},{"key":"10.1016\/j.xphs.2020.11.016_bib26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/02786826.2017.1387642","article-title":"Aerosol diffusion battery: the retrieval of particle size distribution with the help of analytical formulas","volume":"52","author":"Onischuk","year":"2018","journal-title":"Aerosol Sci Technol"},{"key":"10.1016\/j.xphs.2020.11.016_bib27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/02786826.2018.1473839","article-title":"Determination of the aerosol particle size distribution by means of the diffusion battery: analytical inversion","volume":"52","author":"Onischuk","year":"2018","journal-title":"Aerosol Sci Technol"},{"key":"10.1016\/j.xphs.2020.11.016_bib28","first-page":"224506","article-title":"Experimental study of homogeneous nucleation from the bismuth supersaturated vapor: evaluation of the surface tension of critical nucleus","volume":"136","author":"Onischuk","year":"2012","journal-title":"J\u00a0Chem Phys"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920307450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354920307450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:34:07Z","timestamp":1758360847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354920307450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0022354920307450"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2020.11.016","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aerosol Inhalation Delivery of Triazavirin in Mice: Outlooks for Advanced Therapy Against Novel Viral Infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2020.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}